Tag: cell and gene therapy market forecast

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

#Cell and Gene Therapy Market CAGR Outlook And Future Development#_x000D_

The market for cell and gene therapies has experienced significant expansion in recent years. Its valuation is anticipated to increase from $21.33 billion in 2025 to $26.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.9%. In the past, this historical growth can be attributed to factors such as the limited accessibility of cell and gene therapies, the prevailing reliance on conventional treatment modalities, the high cost of early-generation therapies, the rising incidence of oncology and neurological disorders, and a shortage of specialized treatment centers._x000D_

_x000D_

The cell and gene therapy market is anticipated to experience significant expansion in the coming years. Its valuation is projected to reach $60.58 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. This projected growth during the forecast period is fueled by several factors, including the creation of sophisticated CAR-T and genome editing treatments, the proliferation of clinical studies and research initiatives, a greater embrace of personalized medical approaches, increasing governmental aid and financial backing for therapies targeting rare diseases, and the integration of digital solutions for tracking treatment and managing patients. Key developments expected during this period involve a rise in the uptake of CAR-T and stem cell therapies, increased capital expenditure in gene therapy for cancer and rare conditions, the development of individualized and specific cell-based treatments, an increase in hospitals and outpatient surgical centers providing advanced therapies, and the incorporation of genome editing and viral vector-based techniques into standard medical practice._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=92789793&type=smp&name=Cell%20and%20Gene%20Therapy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Cell and Gene Therapy Market Growth Drivers: What’s Behind The Acceleration?#_x000D_

The expansion of active clinical trials is anticipated to propel the future growth of the cell and gene therapy market. These trials are research studies involving human subjects, designed to assess the safety and efficacy of novel medical therapies, procedures, or diagnostic methods. They are crucial for the progress and evolution of cell and gene therapy, providing a secure and regulated setting for evaluating new treatments and gathering information on their safety and effectiveness. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), an organization based in the UK, reported that the number of pharmaceutical industry trials initiated in the UK grew for the second successive year, increasing from 411 in 2022 to 426 in 2023. Consequently, the increasing volume of active clinical trials is stimulating the expansion of the cell and gene therapy market._x000D_

_x000D_

#Cell and Gene Therapy Market Segment Landscape And Growth Outlook#_x000D_

The cell and gene therapy market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Cell Therapy, Gene Therapy _x000D_

2) By Application: Oncology, Neurological Disorders, Other Applications _x000D_

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy_x000D_

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy _x000D_

_x000D_

_x000D_

#Cell and Gene Therapy Market Trends: What’s Defining The Industry’s Next Phase?#_x000D_

Leading companies operating within the cell and gene therapy market are increasingly focusing on introducing agnostic systems to gain a competitive advantage. Agnostic systems are those designed to integrate with a variety of different cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub, a new platform-agnostic system created to improve connectivity across the cell and gene therapy (CGT) treatment journey, thereby enabling an enhanced patient and provider experience. This hub is powered by the company’s customer relationship management system and is engineered to expedite the benefits investigation process, offer a real-time view of therapy development and transportation status, and assist in coordinating patient support._x000D_

_x000D_

#Cell and Gene Therapy Market Competitive Landscape: Who Leads The Industry?#_x000D_

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca _x000D_

_x000D_

#View The Full Cell and Gene Therapy Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/Cell-And-Genes-Therapy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Cell and Gene Therapy Market Regional Split: Which Areas Are Fueling Growth?#_x000D_

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Cell and Gene Therapy Market Growth Potential: How Will Market Size Change Through 2030?

Over the past few years, the cell and gene therapy market has experienced remarkable expansion. Projections indicate that its value will increase from $21.33 billion in 2025 to $26.21 billion in 2026, reflecting a compound annual growth rate (CAGR) of 22.9%. Several factors have driven this historical growth, including the restricted accessibility of cell and gene therapies, a continued dependence on traditional treatment approaches, the elevated cost of earlier therapy versions, a rising prevalence of cancer and neurological conditions, and a shortage of dedicated treatment facilities.

The cell and gene therapy market is projected to undergo rapid expansion over the upcoming years. By 2030, it is forecasted to reach $60.58 billion, advancing at a compound annual growth rate (CAGR) of 23.3%. Several factors are expected to fuel this growth during the forecast period, such as the creation of cutting-edge CAR-T and genome editing therapies, the broadening of clinical trials and research initiatives, a growing focus on personalized medicine, enhanced governmental backing and funding for rare disease treatments, and the incorporation of digital platforms for treatment monitoring and patient management. Key developments anticipated in this period encompass the rising implementation of CAR-T and stem cell therapies, increased funding for gene therapy targeting oncology and rare conditions, a surge in tailored and cell-based treatment approaches, the growth of hospitals and ambulatory surgical centers providing advanced therapies, and the adoption of genome editing and viral vector technologies across therapeutic applications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cell and Gene Therapy Market Development Factors: Which Trends Are Supporting Demand?

An increasing volume of active clinical trials is anticipated to drive expansion in the cell and gene therapy market moving forward. These trials involve research studies carried out with human volunteers to assess the safety and effectiveness of novel medical treatments, interventions, or diagnostic methods. Clinical trials are essential for the progress and refinement of cell and gene therapy, offering a secure and regulated setting where new therapies can be tested and data regarding their safety and efficacy can be gathered. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the number of pharmaceutical industry trials initiated in the UK grew for the second consecutive year, climbing from 411 in 2022 to 426 in 2023. Consequently, the rising count of ongoing clinical trials is fueling growth in the cell and gene therapy market.

Cell and Gene Therapy Market Segment Performance And Strategic Opportunities

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

Cell and Gene Therapy Market Transformation Trends: Which Innovations Are Driving Change?

Major players in the cell and gene therapy sector are intensifying their efforts to develop agnostic systems as a strategy for securing a competitive advantage. These agnostic systems are designed to integrate seamlessly with diverse cell and gene therapy (CGT) software platforms, alongside various biopharmaceutical or provider-facing systems. A notable example occurred in April 2023, when AmerisourceBergen, a healthcare company based in the United States, introduced the Cell and Gene Therapy Integration Hub. This platform-agnostic solution was created to enhance connectivity throughout the CGT treatment process, ultimately improving experiences for both patients and providers. Driven by the company’s customer relationship management system, the hub accelerates the benefits investigation process, delivers real-time updates on therapy development and transportation, and supports the coordination of patient care.

Cell and Gene Therapy Market Key Players: Which Companies Shape Industry Competition?

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Access The Complete Cell and Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Cell and Gene Therapy Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Will Be The Estimated Market Size Of The Cell and Gene Therapy Market By 2030?

The market for cell and gene therapy has witnessed significant expansion over recent years. It is projected to grow from $21.33 billion in 2025 to $26.21 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.9%. Historically, this growth can be attributed to factors such as the limited availability of cell and gene therapies, reliance on conventional treatment modalities, the high cost of early-generation therapies, the growing incidence of oncology and neurological disorders, and a lack of specialized treatment centers.

The cell and gene therapy market size is anticipated to experience substantial growth in the upcoming years. It is predicted to expand to $60.58 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 23.3%. This expansion over the forecast period can be attributed to the progression of advanced CAR-T and genome editing therapies, an increase in clinical trials and research programs, the growing embrace of personalized medicine, enhanced government support and funding for rare disease treatments, and the incorporation of digital platforms for therapy monitoring and patient management. Significant trends during this period are expected to involve the increased adoption of CAR-T and stem cell therapies, a rise in investment for gene therapy in oncology and rare diseases, the development of personalized and targeted cell-based treatments, the expansion of hospitals and ambulatory surgical centers providing advanced therapies, and the integration of genome editing and viral vector-based technologies into clinical practice.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What Important Drivers Are Powering The Cell and Gene Therapy Market Growth?

The increasing number of ongoing clinical trials is projected to fuel the expansion of the cell and gene therapy market moving forward. Clinical trials are investigative studies carried out with human participants to determine the safety and effectiveness of novel medical treatments, interventions, or diagnostic methods. These trials are fundamental to the progress and development of cell and gene therapy, offering a secure and regulated environment to test new therapies and acquire data concerning their safety and efficacy. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based entity, indicated that the quantity of pharmaceutical industry trials initiated in the UK grew for the second successive year, climbing from 411 in 2022 to 426 in 2023. Thus, a rising volume of active clinical trials is stimulating the growth of the cell and gene therapy market.

How Is The Cell and Gene Therapy Market Examined Through Segment Analysis?

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

Which Trends Are Shaping The Cell and Gene Therapy Market Landscape?

Leading companies in the cell and gene therapy market are intensifying their efforts to introduce agnostic systems, aiming to secure a competitive advantage. Agnostic systems are defined as those capable of integrating with various cell and gene therapy (CGT) software platforms, alongside biopharmaceutical or provider-facing platforms. For example, in April 2023, AmerisourceBergen, a US-based healthcare company, unveiled the Cell and Gene Therapy Integration Hub. This novel platform-agnostic system seeks to enhance connectivity throughout the cell and gene therapy (CGT) treatment journey, thereby improving the patient and provider experience. The hub operates using the company’s customer relationship management system and is built to accelerate the benefits investigation process, provide real-time visibility into therapy development and transportation status, and aid in coordinating patient support.

Which Firms Are Competing In The Cell and Gene Therapy Market?

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Access The Complete Cell and Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Which Geographic Region Represents The Largest Cell and Gene Therapy Market Share?

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cell and Gene Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

Browse Through More Reports Similar to the Global Cell and Gene Therapy Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Cell and Gene Therapy Market Between 2026 And 2030?

The cell and gene therapy market has experienced exponential growth in its size over recent years. Projections indicate it will expand from $21.33 billion in 2025 to $26.21 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 22.9%. Historically, this expansion has been driven by factors such as the restricted availability of cell and gene therapies, a prevailing dependence on traditional treatment options, the significant expense associated with initial therapeutic generations, a rising prevalence of oncology and neurological conditions, and an insufficient number of dedicated treatment centers.

The cell and gene therapy market is projected to experience rapid expansion in the coming years. This market is set to reach $60.58 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.3%. Factors contributing to this growth during the forecast period include the advancement of car-t and genome editing therapies, the proliferation of clinical trials and research initiatives, the growing acceptance of personalized medicine, enhanced government backing and financial aid for rare disease treatments, and the incorporation of digital solutions for tracking therapies and managing patients. Key trends anticipated during this period involve the wider uptake of car-t and stem cell therapies, increased financial commitment to gene therapy for oncology and rare diseases, an increase in personalized and targeted cell-based treatments, the proliferation of hospitals and ambulatory surgical centers providing cutting-edge therapies, and the incorporation of genome editing and viral vector-based technologies into clinical applications.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What Leading Drivers Are Supporting The Cell and Gene Therapy Market Expansion?

The increasing volume of active clinical trials is anticipated to drive the expansion of the cell and gene therapy market in the future. These trials represent investigations carried out involving human subjects to assess the safety and efficacy of novel medical approaches, treatments, or diagnostic methods. They are crucial for the progress and evolution of cell and gene therapy, offering a secure and regulated setting for evaluating emerging therapies and gathering information regarding their safety and effectiveness. An example of this trend is observed in December 2024, where the Association of the British Pharmaceutical Industry (ABPI), an organization based in the UK, reported an increase in pharmaceutical industry trials initiated in the UK for the second year in a row, escalating from 411 in 2022 to 426 in 2023. Consequently, the rising count of active clinical trials serves as a key driver for the expansion of the cell and gene therapy market.

Which Segment Classifications Are Used In The Cell and Gene Therapy Market Segment Analysis?

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

What Market Trends Are Affecting The Cell and Gene Therapy Market?

Leading companies operating in the cell and gene therapy market are increasingly focusing on implementing agnostic systems to gain a competitive advantage. Agnostic systems are those designed to integrate with a diverse range of different cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub. This new platform-agnostic system is intended to improve connectivity throughout the cell and gene therapy (CGT) treatment journey, thereby enabling an enhanced patient and provider experience. The hub, powered by the company’s customer relationship management system, is engineered to accelerate the benefits investigation process, provide a real-time view of therapy development and transportation status, and assist in coordinating patient support.

Which Firms Are Contributing To The Cell and Gene Therapy Market Ecosystem?

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Get The Full Cell and Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Which Region Represents The Largest Share Of The Cell and Gene Therapy Market?

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cell and Gene Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Browse Through More Reports Similar to the Global Cell and Gene Therapy Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Cell and Gene Therapy Market Over The Period 2026–2030?

The cell and gene therapy market size has experienced rapid growth in recent years. It is projected to increase from $21.33 billion in 2025 to $26.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.9%. Historically, this growth can be attributed to factors such as the limited availability of cell and gene therapies, the dependence on conventional treatment modalities, the high cost of early-generation therapies, the increasing incidence of oncology and neurological disorders, and the scarcity of specialized treatment centers.

The cell and gene therapy market is anticipated to experience substantial expansion over the upcoming years. Its size is projected to reach $60.58 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.3%. This growth during the projected timeframe is largely driven by factors such as the advancement of sophisticated CAR-T and genome editing treatments, the broadening of clinical trials and research initiatives, a greater embrace of personalized medical approaches, augmented government backing and financing for therapies addressing rare diseases, and the incorporation of digital tools for overseeing treatment and managing patients. Key trends expected within this period encompass a growing acceptance of CAR-T and stem cell therapies, a surge in investment directed towards gene therapy for cancer and uncommon conditions, an increase in customized and focused cell-based treatments, the proliferation of hospitals and outpatient surgical centers providing cutting-edge therapies, and the incorporation of genome editing and viral vector-based techniques into routine clinical applications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What Underlying Factors Are Accelerating The Growth Of The Cell and Gene Therapy Market?

The increasing volume of ongoing clinical trials is anticipated to propel the expansion of the cell and gene therapy market. These trials are research studies involving human participants, designed to assess the safety and efficacy of novel medical treatments, interventions, or diagnostic methods. They play a vital role in the development and advancement of cell and gene therapy, providing a secure and regulated setting to evaluate new therapies and collect data on their safety and effectiveness. For instance, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported in December 2024 that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Consequently, the expanding number of ongoing clinical trials is driving the growth of the cell and gene therapy market.

How Is The Cell and Gene Therapy Market Divided Into Its Major Segments?

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

How Are Trends Transforming The Cell and Gene Therapy Market Landscape?

Leading companies operating within the cell and gene therapy market are intensifying their efforts to introduce agnostic systems, aiming to secure a competitive advantage. Agnostic systems are defined as those capable of integrating with a diverse range of cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. Illustratively, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub. This new platform-agnostic system is designed to enhance connectivity throughout the cell and gene therapy (CGT) treatment journey, ultimately fostering a superior patient and provider experience. The hub is powered by the company’s customer relationship management system and is intended to accelerate the benefits investigation process, provide a real-time perspective on therapy development and transportation status, and aid in coordinating patient support.

Who Are The Prominent Organizations Shaping The Cell and Gene Therapy Market?

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Read the full cell and gene therapy market report here:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Which Region Is Projected To Dominate The Cell and Gene Therapy Market During The Forecast Period?

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell and Gene Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

Browse Through More Reports Similar to the Global Cell and Gene Therapy Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Cell and Gene Therapy Market Over The Period 2026–2030?

The cell and gene therapy market size has experienced rapid growth in recent years. It is projected to increase from $21.33 billion in 2025 to $26.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 22.9%. Historically, this growth can be attributed to factors such as the limited availability of cell and gene therapies, the dependence on conventional treatment modalities, the high cost of early-generation therapies, the increasing incidence of oncology and neurological disorders, and the scarcity of specialized treatment centers.

The cell and gene therapy market is anticipated to experience substantial expansion over the upcoming years. Its size is projected to reach $60.58 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.3%. This growth during the projected timeframe is largely driven by factors such as the advancement of sophisticated CAR-T and genome editing treatments, the broadening of clinical trials and research initiatives, a greater embrace of personalized medical approaches, augmented government backing and financing for therapies addressing rare diseases, and the incorporation of digital tools for overseeing treatment and managing patients. Key trends expected within this period encompass a growing acceptance of CAR-T and stem cell therapies, a surge in investment directed towards gene therapy for cancer and uncommon conditions, an increase in customized and focused cell-based treatments, the proliferation of hospitals and outpatient surgical centers providing cutting-edge therapies, and the incorporation of genome editing and viral vector-based techniques into routine clinical applications.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What Underlying Factors Are Accelerating The Growth Of The Cell and Gene Therapy Market?

The increasing volume of ongoing clinical trials is anticipated to propel the expansion of the cell and gene therapy market. These trials are research studies involving human participants, designed to assess the safety and efficacy of novel medical treatments, interventions, or diagnostic methods. They play a vital role in the development and advancement of cell and gene therapy, providing a secure and regulated setting to evaluate new therapies and collect data on their safety and effectiveness. For instance, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported in December 2024 that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Consequently, the expanding number of ongoing clinical trials is driving the growth of the cell and gene therapy market.

How Is The Cell and Gene Therapy Market Divided Into Its Major Segments?

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

How Are Trends Transforming The Cell and Gene Therapy Market Landscape?

Leading companies operating within the cell and gene therapy market are intensifying their efforts to introduce agnostic systems, aiming to secure a competitive advantage. Agnostic systems are defined as those capable of integrating with a diverse range of cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. Illustratively, in April 2023, AmerisourceBergen, a US-based healthcare company, launched the Cell and Gene Therapy Integration Hub. This new platform-agnostic system is designed to enhance connectivity throughout the cell and gene therapy (CGT) treatment journey, ultimately fostering a superior patient and provider experience. The hub is powered by the company’s customer relationship management system and is intended to accelerate the benefits investigation process, provide a real-time perspective on therapy development and transportation status, and aid in coordinating patient support.

Who Are The Prominent Organizations Shaping The Cell and Gene Therapy Market?

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Read the full cell and gene therapy market report here:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Which Region Is Projected To Dominate The Cell and Gene Therapy Market During The Forecast Period?

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell and Gene Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

Browse Through More Reports Similar to the Global Cell and Gene Therapy Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the cell and gene therapy market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Cell and Gene Therapy Market between 2026 and 2030?

The cell and gene therapy market size has experienced rapid expansion in recent years. This market is projected to expand from $21.33 billion in 2025 to $26.21 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.9%. Factors contributing to its historical growth include the limited availability of cell and gene therapies, a reliance on conventional treatment methods, the high cost of initial-generation therapies, an increasing prevalence of oncology and neurological conditions, and a scarcity of specialized treatment facilities.

The cell and gene therapy market size is projected to experience substantial growth over the next few years, reaching $60.58 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.3%. This expansion during the forecast period is fueled by advancements in car-t and genome editing therapies, the broadening of clinical trials and research programs, a wider embrace of personalized medicine, increased government backing and funding for rare disease treatments, and the incorporation of digital platforms for therapy oversight and patient management. Significant trends anticipated during this period encompass the growing utilization of car-t and stem cell therapies, augmented investment in gene therapy for oncology and rare diseases, a surge in personalized and targeted cell-based treatments, the expansion of hospital and ambulatory surgical centers providing advanced therapies, and the integration of genome editing and viral vector-based technologies into clinical practice.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Cell and Gene Therapy Market?

The future expansion of the cell and gene therapy market is anticipated to be propelled by a rising number of ongoing clinical trials. These research studies are conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. Clinical trials play a crucial role in the development and advancement of cell and gene therapy, offering a secure and regulated setting to test new therapies and gather data on their safety and efficacy. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the number of pharmaceutical industry trials initiated in the UK increased for the second consecutive year, growing from 411 in 2022 to 426 in 2023. Therefore, the increasing number of ongoing clinical trials is actively driving the growth of the cell and gene therapy market.

How Is The Cell and Gene Therapy Market Organized Into Various Segments?

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

What Industry Trends Are Transforming The Cell and Gene Therapy Market?

Major companies active in the cell and gene therapy market are increasingly focusing on introducing agnostic systems to gain a competitive advantage. Agnostic systems are defined as those that seamlessly integrate with various cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, unveiled the Cell and Gene Therapy Integration Hub. This new platform-agnostic system aims to enhance connectivity throughout the cell and gene therapy (CGT) treatment journey, facilitating an improved patient and provider experience. The hub operates using the company’s customer relationship management system and is engineered to expedite the benefits investigation process, offer a real-time perspective on therapy development and transportation status, and assist in coordinating patient support.

Who Are The Core Companies Influencing Trends In The Cell and Gene Therapy Market?

Major companies operating in the cell and gene therapy market are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Stempeutics Research Pvt. Ltd., EdiGene Inc., Takara Bio, Oxford Biomedica plc, Merck, GenScript, Cellular Biomedicine Group, inStem, Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Which Regions Are Projected To Dominate The Cell and Gene Therapy Market In The Coming Years?

North America was the largest region in the cell and gene therapy market in 2025. The regions covered in the cell and gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cell and Gene Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

Browse Through More Reports Similar to the Global Cell and Gene Therapy Market 2026, By The Business Research Company

Cancer Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Is the Growth Rate of the Cell and Gene Therapy Market?#_x000D_

The market size for cell and gene therapy has witnessed massive expansion in the past few years. It is projected to escalate from $12.01 billion in 2024 to $15.48 billion in 2025, with a compound annual growth rate (CAGR) of 28.9%. This growth during the historical period can be ascribed to the surge in investments towards cell and gene therapies, advancements in the research and development sector, progress in cancer drug discovery, an increase in public-private collaborations, robust economic development in emerging markets, enhanced healthcare spending and an upsurge in expenditure dedicated to pharmaceutical R&D._x000D_

_x000D_

#What Growth Rate Is Forecasted for the Cell and Gene Therapy Market by 2029?#_x000D_

The dimension of the cell and gene therapy market is set to witness impressive expansion in the upcoming years, ballooning up to $29.15 billion in 2029, demonstrating an annual compound growth rate of 17.1%. Factors contributing to growth during the forecast period include the growing instances of chronic diseases and prevailing cancer, an increase in the elderly population, and a heightened interest in cell and gene therapies, as well as escalated spending in healthcare. Key trends projected for the period of forecast include prioritization of advanced treatments such as chimeric antigen receptor (CAR) T-cell, substantial investment in research and securing funding, implementing strategic partnerships to incorporate state-of-the-art technologies, focusing on the construction of gene or genome editing tools, especially CRISPR, merger or acquisition of competitor firms, stepping up the volume of studies in the pipeline to create novel cell and gene therapies, and putting funds into the extension of manufacturing facilities._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp_x000D_

_x000D_

#Which Key Companies Are Shaping the Future of the Cell and Gene Therapy Market?#_x000D_

Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca_x000D_

_x000D_

#Which Factors Are Driving Demand in the Cell and Gene Therapy Industry?#_x000D_

The cell and gene therapy (CGT) market has experienced significant growth due to consistent investments and consolidation within the cell and gene therapy fields. Recognizing the potential of the CGT market, 80% of the top 20 biopharmaceutical companies in terms of revenue have added CGT products to their portfolio. Specifically, in 2023, the BioIndustry Association (BIA), a UK-based life sciences and biotech industry representative body, reported that UK cell and gene therapy companies claimed more than half of the venture capital funding gained by European firms. Typically, the UK accounts for approximately a third of all European venture capital investments in the life sciences sector, which emphasizes the strength of their cell and gene therapy sector. Constant investment and consolidation in CGT production have resulted in increased production capacity and market growth. For instance, in October 2024, Purespring Therapeutics, a UK-based biotech firm, secured $105 million in funding to back the development of gene therapies for kidney diseases, including a phase 1/2 trial of an experimental treatment for immunoglobulin A nephropathy (IgAN). Purespring uses adeno-associated viruses (AAVs) to administer its gene therapies._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp_x000D_

_x000D_

#How Is the Cell and Gene Therapy Market Segmented by Several Divisions?#_x000D_

The cell and gene therapy market covered in this report is segmented –_x000D_

_x000D_

1) By Product: Cell Therapy, Gene Therapy_x000D_

2) By Application: Oncology, Neurological Disorders, Other Applications_x000D_

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy_x000D_

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy_x000D_

_x000D_

_x000D_

#What are the Emerging Market Trends Driving the Growth of the Cell and Gene Therapy Industry?#_x000D_

The cell and gene therapy (CGT) market is being significantly influenced by the rise of Chimeric antigen receptor (CAR) T-cell therapy. This therapy involves a combination of cell and gene therapy, where specialized T cells are gathered from the patient’s blood, and then genetically tinkered to generate modified receptors on their surfaces, recognized as chimeric antigen receptors (CARs). These altered T cells, equipped with particular constructs (receptors), are reintroduced into the patient. Subsequently, these re-engineered receptors on the T cells facilitate the targeting of the cancer cell’s surface antigen, culminating in the elimination of tumorous cells in the affected patients. As an example, in June 2022, the US-based pharmaceutical firm, Bristol-Myers Squibb Company, successfully gained approval from the United States Food and Drug Administration (US FDA) for their CAR T cell therapy named Breyanzi. This therapy is intended for treating adult patients suffering from large B-cell lymphoma (LBCL), which includes conditions like diffuse large B-cell lymphoma. Breyanzi is a distinct CAR T cell therapy, created from a patient’s own T cells, which are harvested and genetically reprogrammed into CAR T cells, then reintroduced into the patient through infusion as a one-time treatment._x000D_

_x000D_

#Access The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report_x000D_

_x000D_

#Which Regions Are Driving Growth in the Cell and Gene Therapy Market?#_x000D_

North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Purchase The Full Report Today:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472_x000D_

_x000D_

#This Report Delivers Insight On: #_x000D_

1. How big is the cell and gene therapy market, and how is it changing globally?_x000D_

2. Who are the major companies in the cell and gene therapy market, and how are they performing?_x000D_

3. What are the key opportunities and risks in the cell and gene therapy market right now?_x000D_

4. Which products or customer segments are growing the most in the cell and gene therapy market?_x000D_

5. What factors are helping or slowing down the growth of the cell and gene therapy market?_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 2071930708_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cell and gene therapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What is the Anticipated CAGR of the Cell and Gene Therapy Market, and What Factors Will Drive It?

The market size for cell and gene therapy has seen a remarkable increase in the recent past. It is projected to surge from a market value of $12.01 billion in 2024 to a staggering $15.48 billion in 2025, reflecting a compound annual growth rate (CAGR) of 28.9%. Various factors like increased investment in cell and gene therapy, enhanced research and development activities, progress in cancer drug innovation, an upswing in public and private sector collaborations, robust economic growth witnessed in budding markets, augmented healthcare spending, and a rise in expenditure on pharmaceutical research and development contribute to the growth observed in the historic period.

Swift expansion is predicted for the cell and gene therapy market, which is projected to rise to $29.15 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.1%. This surge over the forecast period can be credited to factors such as the growing incidence of cancer and chronic illnesses, an increasing elderly population, heightened focus on cell and gene therapy, and upsurge in healthcare spending. Key trends expected during the forecast period encompass emphasis on sophisticated therapies like chimeric antigen receptor (CAR) T-cell therapy, dedication towards various research endeavors and securing funding, executing strategic collaborations to amalgamate cutting-edge technologies, focus on the creation of gene or genome editing instruments, particularly CRISPR, forming partnerships or takeover of rival firms, elevating the count of pipeline investigations to devise cell and gene therapies, and investment in the expansion of manufacturing facilities.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

What External and Internal Drivers Are Contributing to the Growth of theCell and Gene Therapy Market?

Investment stability and amalgamation played key roles in the development of the cell and gene therapy (CGT) market. The potential of the CGT market was realized by 16 of the top 20 revenue-earning biopharmaceutical firms, all of which introduced CGT products into their offerings. The BioIndustry Association (BIA), a UK-based entity that represents the biotech and life sciences industries, noted that in 2023, over 55% of venture capital secured by European enterprises was obtained by UK cell and gene therapy corporations. Typically, the UK is responsible for approximately one third of all European venture capital investments in life sciences, demonstrating the prominence of its CGT sector. The CGT manufacturing capacity has seen stable investments and collaboration, resulting in an amplified production capacity, thus fostering market expansion. To illustrate, in October 2024, Purespring Therapeutics, a UK biotech firm, secured $105 million in funding to assist in the development of gene therapies for kidney diseases, including a phase 1/2 experimental treatment trial for immunoglobulin A nephropathy (IgAN). Adeno-associated viruses (AAVs) are employed by Purespring to deliver its gene therapies to the body.

What Segment Types Define the Cell and Gene Therapy Market Structure?

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Cell and Gene Therapy Market?

North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Long-Term Trends Are Transforming the Competitive Landscape of the Cell and Gene Therapy Market?

The cell and gene therapy (CGT) market is being revolutionized by Chimeric antigen receptor (CAR) T-cell therapy. This therapeutic approach involves collecting T cells from a patient’s blood, genetically engineering them to develop chimeric antigen receptors (CARs) – a type of modified receptor, and reintroducing these modified T cells back into the patient. These reengineered T cells, possessing unique receptor structures, aid in identifying and targeting cancer cell surface antigens, ultimately leading to the destruction of tumor cells. For example, in June 2022, Bristol-Myers Squibb Company, a US pharmaceutical firm, gained approval from the United States Food and Drug Administration (US FDA) for its CAR T cell therapy Breyanzi. This approval was for treating adult patients suffering from large B-cell lymphoma (LBCL), including the diffuse large B-cell lymphoma. Breyanzi is a unique CAR T cell therapy that uses a patient’s own T cells, which undergo collection and re-engineering to become CAR T cells for reintroduction into the patient as a single-administration treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

What Is the Definition of the Cell and Gene Therapy Market?

Gene therapy involves the transmission of genetic material, typically in the form of a carrier or vector, and the uptake of the gene into the proper body cells. Cell therapy includes introducing cells into the patient with the appropriate function. Some procedures combine cell therapy with gene therapy.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theCell and Gene Therapy Market?

The cell and gene therapy (CGT) market has grown due to continuous investments and consolidations within cell and gene therapies. Recognizing the potential of this market, 16 of the top 20 big biopharmaceutical firms by revenue have included CGT products in their range. For example, in 2023, according to the BioIndustry Association (BIA), which is UK-based and represents the life sciences and biotech sector, cell and gene therapy companies from the UK secured more than half of venture capital investments received by European companies. Typically, the UK accounts for about a third of all European venture capital investments in life sciences, which underscores the strength of its cell and gene therapy industry. Continuous investments and mergers in CGT production capacity have resulted in increased production and further market growth. For example, in October 2024, Purespring Therapeutics, a UK-based biotechnology firm, received a funding of $105 million to support kidney disease gene therapies development, including a phase 1/2 trial of a new treatment for immunoglobulin A nephropathy (IgAN). Purespring uses adeno-associated viruses (AAVs) to deliver its gene therapies into the body.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3472&type=smp

#What is the Anticipated CAGR of theCell and Gene Therapy Market, and What Factors Will Drive It?

In recent years, the cell and gene therapy market has experienced significant growth. It is projected to increase from a size of $12.01 billion in 2024 to a staggering $15.48 billion in 2025 with a compound annual growth rate (CAGR) of 28.9%. The historic surge in growth is driven by increased financial investment in cell and gene therapies, advancements in research and development, progress in the discovery of cancer drugs, an upswing in public-private collaborations, a robust economic upturn in developing markets, heightened healthcare costs, and an increase in expenditure on pharmaceutical research and development.

Over the coming years, the cell and gene therapy market is predicted to experience swift expansion, with projections indicating that it will reach $29.15 billion by 2029. This growth corresponds to a compound annual growth rate (CAGR) of 17.1%. Factors contributing to this growth during the forecast period include growing cases of cancer and chronic illnesses, an increase in the aging population, heightened emphasis on cell and gene therapy, and healthcare expenditure increases. Key trends for the forecast period include placing emphasis on cutting-edge therapies such as chimeric antigen receptor (CAR) T-cell therapy, focusing on launching various research initiatives and securing funding, implementing strategic collaborations to incorporate advanced technology, focusing on the development of gene or genome editing tools especially CRISPR, merging with or acquiring rivals, upscaling the number of pipeline research to develop cell and gene therapies, and investment in expanding production facilities.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3472

Which Upcoming Market Trends and Innovations Are Set to Influence theCell and Gene Therapy Market’s Path Forward?

The cell and gene therapy (CGT) market is being revolutionized by Chimeric antigen receptor (CAR) T-cell therapy. This therapy is a fusion of cell and gene therapy where T cells are modified with genetically engineered receptors, called Chimeric antigen receptors (CARs), after being collected from a patient’s blood. The modified T cells, now featuring specialized receptors, are then reintroduced into the patient’s body. These receptors aid in identifying and attacking cancer cells’ surface antigens, leading to the elimination of tumor cells. To illustrate, Bristol-Myers Squibb Company, an American pharmaceutical firm, got approval from the US Food and Drug Administration (US FDA) for its CAR T cell therapy Breyanzi in June 2022. This therapy is particularly meant for adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi, a unique CAR T cell therapy, is fabricated from a patient’s T cells, which are collected, genetically altered into CAR T cells, and then infused back into the patient as a stand-alone treatment.

Who Are the Dominant Market Players Pushing the Boundaries of theCell and Gene Therapy Market?

Major companies operating in the cell and gene therapy market include Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Oxford Biomedica plc, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma Plc, AstraZeneca

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

What Are the Core Segments of the Cell and Gene Therapy Market, and How Do They Contribute to Growth?

The cell and gene therapy market covered in this report is segmented –

1) By Product: Cell Therapy, Gene Therapy

2) By Application: Oncology, Neurological Disorders, Other Applications

3) By End User: Hospitals, Ambulatory Surgical Centers, Cancer Care Centers, Wound Care Centers, Other End-Users

Subsegments:

1) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy, CAR-T Cell Therapy

2) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing Technologies, Antisense Oligonucleotide Therapy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=3472&type=smp

What Regions Are Dominating the Cell and Gene Therapy Market Growth?

North America was the largest region in the cell and gene therapy market in 2024. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Cell and Gene Therapy Market 2025, By The Business Research Company:

nucleic acid based gene therapy market, global nucleic acid based gene therapy market, nucleic acid based gene therapy market trends, nucleic acid based gene therapy market forecast, nucleic acid based gene therapy market analysis, nucleic acid-based therapeutics market, nucleic acid based gene therapy global market report 2021, nucleotide therapy market, gene therapy industry report, nucleic acid based gene therapy market report 2020

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market

Alpha Mannosidosis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/alphas-mannosidosis-global-market-report

Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities And Strategies To 2031

https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-market

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: